Full Press Release Details
Therapeutics Acquires Xeglyze (abametapir) Topical Treatment for Head Lice
N.C., January 5, 2026 - Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing
innovative therapeutic products for unmet patient needs ("Pelthos"), today announced it has acquired Xeglyze (abametapir)
from Hatchtech Pty Ltd., an Australian biotech company, for $1.8 million.
is a pediculicide indicated for the topical treatment of head lice infestation in patients 6 months of age and older. The prescription
medication was approved by the U.S. Food and Drug Administration ("FDA") in July 2020.
acquisition will provide Pelthos with the ability to commercialize Xeglyze worldwide, and there are no future milestone, royalty or other
payments owed to Hatchtech.
"This acquisition allows us to add another complementary FDA-approved product to our portfolio," said Scott Plesha, CEO of
Pelthos. "Xeglyze is a highly differentiated product with a strong clinical profile. We believe it aligns well with our existing
products and commercial infrastructure, making this an attractive investment opportunity for Pelthos. This addition will allow us to continue
to execute on our strategy of commercializing innovative therapeutic products in 2026 that address unmet patient needs, delivering long-term
value for our shareholders."
plans to relaunch Xeglyze in the first half of 2027.
the U.S., infestation with head lice is most common among preschool- and elementary-school age children and their household members and
caretakers. An estimated 6 to 12 million infestations occur each year in the U.S. among children 3 to 11 years of age. Some studies suggest
that girls get head lice more often than boys, due to more frequent head-to-head contact.
how common head lice is, there have been few major advances in controlling infestations in recent years," said Stephen W. Stripling,
MD, Pediatrician, at The Medical University of South Carolina. "Most head lice products have little ovicidal activity and require
two treatments approximately 7 to 10 days apart, with the second application required to treat those lice that survived the first treatment
and were not physically removed by nit combing. Not complying with this regimen and having trouble choosing the optimal time for the
second application are major drawbacks in using these products. Xeglyze has demonstrated both ovicidal and lousicidal activity and offers
the potential for a more effective treatment using only a single, 10-minute application."
Xeglyze (abametapir)
is a novel, patent protected prescription medication indicated for the topical treatment of head lice infestation in patients 6 months
of age and older. Abametapir, the active ingredient in Xeglyze, inhibits metalloproteinases that have a role in physiological processes
critical to egg development and survival of lice. The single, 10 minute application does not require nit combing and has sufficient
volume in each bottle to treat either short or long hair.
and Usage: Xeglyze is a pediculicide indicated for the topical treatment of head lice infestation in patients 6 months of age and
older. Xeglyze should be used in the context of an overall lice management program:
Reactions: Most common adverse reactions (incidence of 1%) were erythema, rash, skin burning sensation, contact dermatitis,
vomiting, eye irritation, pruritus, and hair color changes.
complete safety information and product dosing instructions, refer to the product
Pelthos Therapeutics
Therapeutics is a biopharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help
patients with unmet treatment burdens. The company's lead product ZELSUVMI (berdazimer) topical gel, 10.3%, for the treatment
of molluscum contagiosum, was approved by the U.S. Food and Drug Administration in 2024. More information is available at www.pelthos.com.
Follow Pelthos on LinkedIn and X.
press release contains forward-looking statements, as defined in Section 21E of the Securities Exchange Act of 1934, regarding Pelthos'
current expectations. All statements, other than statements of historical fact, could be deemed to be forward-looking statements. In
some instances, words such as "plans," "believes," "expects," "anticipates," and "will,"
and similar expressions, are intended to identify forward-looking statements. Readers are cautioned not to place undue reliance on these
forward-looking statements, which reflect our good faith beliefs (or those of the indicated third parties) and speak only as of the date
hereof. These forward-looking statements include, without limitation, references to our expectations regarding (i) our belief that the
acquisition of Xeglyze will provide the Company with the ability to commercialize the product worldwide, (ii) our belief that Xeglyze
aligns well with the Company's existing products and commercial infrastructure, (iii) our belief that Xeglyze is an attractive
investment opportunity for the Company, (iv) our belief that the acquisition of Xeglyze will allow the Company to continue to execute
on its strategy of commercializing therapeutic products in 2026 that address unmet patient needs and delivering long-term value to the
Company's shareholders, (v) the Company's plans and timeline with respect to the launch of Xeglyze, and (vii) the Company's
future opportunities, strategy and plans in the market. These statements are not guarantees of future performance and are subject to
certain risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ materially
from those set forth in such forward-looking statements include, but are not limited to, risks and uncertainties related to there being
no guarantee that the trading price of the combined company's Common Stock will be indicative of the combined company's value
or that the combined company's Common Stock will become an attractive investment in the future; we may rely on collaborative partners
for milestone payments, royalties, materials revenue, contract payments and other revenue projections and may not receive expected revenue;
we and our partners may not be able to timely or successfully advance any product(s) in our internal or partnered pipeline or receive
regulatory approval and there may not be a market for the product(s) even if successfully developed and approved; and changes in general
economic conditions, including as a result of war, conflict, epidemic diseases, the implementation of tariffs, and ongoing or future
litigation could expose us to significant liabilities and have a material adverse effect on us. These and other risks and uncertainties
are described more fully in our filings with the U.S. Securities and Exchange Commission. The information in this press release is provided
only as of the date of this press release, and we undertake no obligation to update any forward-looking statements contained in this
press release based on new information, future events, or otherwise, except as required by law.
Mike Moyer, Managing Director